Thin Gingiva, Thin Gingival Biotype
Conditions
Keywords
C-PRF, I-PRF, VISTA Technique
Brief summary
This clinical trial aims to evaluate the effects of injectable platelet-rich fibrin (I-PRF) and concentrated platelet-rich fibrin (C-PRF) on gingival phenotype in patients undergoing mucogingival surgery with the VISTA technique. Changes in gingival thickness and width of keratinized gingiva will be assessed using both manual and digital methods.
Detailed description
The study is designed as a randomized controlled clinical trial including 30 patients, divided into two groups: I-PRF and C-PRF. All participants receive a mucogingival procedure using the VISTA technique followed by four sessions of PRF injections (one during surgery and three at 10-day intervals). The primary outcomes are changes in gingival thickness and the width of keratinized gingiva, measured manually and digitally at baseline, 1 month, 3 months and 6 months. The aim is to compare the effectiveness of I-PRF and C-PRF on soft tissue enhancement.
Interventions
BIOLOGICALConcentrated PRF
Injectable platelet-rich fibrin was prepared using low-speed centrifugation and injected using the same protocol as C-PRF (1 surgical + 3 injection sessions at 10-day intervals).
BIOLOGICALInjectable PRF
Injectable platelet-rich fibrin was prepared using low-speed centrifugation and injected using the same protocol as C-PRF (1 surgical + 3 injection sessions at 10-day intervals).
Sponsors
Inonu University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Two-arm parallel design comparing the effects of I-PRF and C-PRF on gingival phenotype using VISTA technique.
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
Systemically healthy individuals (ASA I) Age between 18 and 45 years Non-smokers Gingival thickness ≤ 0.8 mm in the mandibular anterior region No restorations, missing teeth, or supernumerary teeth in the mandibular anterior region Full-mouth plaque index (PI) \< 15% Full-mouth bleeding on probing (BOP) \< 15%
Exclusion criteria
Presence of systemic disease or coagulation disorders Use of antibiotics or anti-inflammatory drugs within the last 3 months Smoking History of bruxism Pregnancy or lactation Ongoing orthodontic treatment Use of medications affecting gingival phenotype (e.g., calcium channel blockers, anticonvulsants) Presence of infection, lesion, or trauma at the surgical site History of periodontal surgery in the relevant area
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in gingival thickness | Baseline, 1 month, 3 months and 6 months. | Gingival thickness will be measured manually (using a spreader) to assess the effect of I-PRF and C-PRF over time. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in width of keratinized gingiva | Baseline, 1 month, 3 months and 6 months | The width of keratinized gingiva will be measured manually using a periodontal probe to evaluate the soft tissue augmentation potential of C-PRF and I-PRF. |
Countries
Turkey (Türkiye)
Outcome results
None listed